The focus of this research program since its inception has been variable repolarization in the heart, and its relation to abnormal cardiac rhythms, a continuing public health problem. Investigation of arrhythmia susceptibility in the intact heart has been greatly advanced by studies of monogenic arrhythmia diseases such as the congenital long QT syndromes or the Brugada Syndrome. A finding that is especially relevant to the present proposal is that mutation carriers may be phenotypically normal, and a number of mechanisms have been proposed to explain such variable penetrance. The present proposal will build on extensive preliminary data to test the hypothesis that variable cardiac sodium channel delivery to the cell surface can determine the clinical phenotype of sodium channel-linked forms of monogenic disease. A key feature of this proposal is that we will for the first time systematically extend studies we and others have conducted in vitro showing misprocessing of mutant long QT syndrome ion channels to the intact heart. This will be accomplished by implementing recombinase-mediated cassette exchange, a new technique that allows rapid and efficient generation of multiple mouse lines bearing mutant DMAs at a target locus. We have successfully targeted the sodium channel locus for cassette exchange in embryonic stem cells, and have now validated the method by generating mice-with normal sodium channel function-in which expression of the wild-type murine sodium channel gene has been ablated, and replaced by the human isoform.
Specific aim 1 will assess cell surface expression in vitro of LQT3 and Brugada Syndrome mutations chosen from domains of the channel predicted to exhibit specific secondary structures.
In specific aim 2, we will study whole heart phenotypes, including arrhythmia susceptibility, in mice we generate by cassette exchange to express humanized and epitope-tagged wild-type or mutant (LQT3 or Brugada Syndrome) channels.
Specific aim 3 will use these mouse models to manipulate cell surface sodium channel expression. The outcome of this research will not only advance our understanding of the pathophysiology of monogenic congenital arrhythmia syndromes, but also will point to more general approaches for therapeutic manipulation of ion channel expression.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Electrical Signaling, Ion Transport, and Arrhythmias Study Section (ESTA)
Program Officer
Wang, Lan-Hsiang
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Roden, Dan M (2016) Pharmacogenetics of Potassium Channel Blockers. Card Electrophysiol Clin 8:385-93
Roden, Dan M (2014) Personalized medicine to treat arrhythmias. Curr Opin Pharmacol 15:61-7
Roden, Dan M (2014) Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs. Card Electrophysiol Clin 6:695-704
Roden, Dan M (2014) The Brugada ECG and schizophrenia. Circ Arrhythm Electrophysiol 7:365-7
Yang, Tao; Chun, Young Wook; Stroud, Dina M et al. (2014) Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation 130:224-34
Weeke, Peter; Roden, Dan M (2014) Applied pharmacogenomics in cardiovascular medicine. Annu Rev Med 65:81-94
Roden, Dan M; Knollmann, Björn C (2014) Dantrolene: from better bacon to a treatment for ventricular fibrillation. Circulation 129:834-6
Bezzina, Connie R; Barc, Julien; Mizusawa, Yuka et al. (2013) Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet 45:1044-9
Roden, Dan M; Hong, Charles C (2013) Stem cell-derived cardiomyocytes as a tool for studying proarrhythmia: a better canary in the coal mine? Circulation 127:1641-3
Yang, Tao; Smith, Jarrod A; Leake, Brenda F et al. (2013) An allosteric mechanism for drug block of the human cardiac potassium channel KCNQ1. Mol Pharmacol 83:481-9

Showing the most recent 10 out of 83 publications